Total Payments
$1.5M
2024 Payments
$273,956
Companies
28
Transactions
1,368
Medicare Patients
451
Medicare Billing
$77,045
Payment Breakdown by Category
Other$971,291 (65.5%)
Consulting$247,793 (16.7%)
Travel$204,197 (13.8%)
Research$31,230 (2.1%)
Food & Beverage$25,886 (1.7%)
Education$2,292 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $878,231 | 239 | 59.2% |
| Consulting Fee | $247,793 | 82 | 16.7% |
| Travel and Lodging | $204,197 | 580 | 13.8% |
| Honoraria | $81,825 | 26 | 5.5% |
| Unspecified | $31,230 | 10 | 2.1% |
| Food and Beverage | $25,886 | 363 | 1.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $10,736 | 4 | 0.7% |
| Education | $2,292 | 63 | 0.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $500.00 | 1 | 0.0% |
Payments by Type
General
$1.5M
1,358 transactions
Research
$31,230
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $331,354 | 413 | $0 (2024) |
| Celgene Corporation | $292,513 | 201 | $0 (2024) |
| Incyte Corporation | $257,307 | 220 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $141,388 | 101 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $90,762 | 78 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $77,894 | 87 | $0 (2024) |
| TAIHO ONCOLOGY, INC. | $70,771 | 56 | $0 (2024) |
| SOBI, INC | $52,555 | 32 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $36,007 | 44 | $0 (2020) |
| Apellis Pharmaceuticals, Inc. | $33,866 | 32 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $273,956 | 210 | Alexion Pharmaceuticals, Inc. ($102,270) |
| 2023 | $217,943 | 184 | Alexion Pharmaceuticals, Inc. ($76,328) |
| 2022 | $240,633 | 220 | E.R. Squibb & Sons, L.L.C. ($79,479) |
| 2021 | $135,693 | 109 | Celgene Corporation ($74,485) |
| 2020 | $115,468 | 73 | Celgene Corporation ($74,517) |
| 2019 | $158,893 | 164 | Celgene Corporation ($47,955) |
| 2018 | $164,278 | 176 | Celgene Corporation ($48,332) |
| 2017 | $175,823 | 232 | Alexion Pharmaceuticals, Inc. ($40,148) |
All Payment Transactions
1,368 individual payment records from CMS Open Payments — Page 1 of 55
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | SOBI, INC | VONJO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/20/2024 | SOBI, INC | VONJO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/20/2024 | Geron Corporation | RYTELO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/20/2024 | SOBI, INC | VONJO (Drug) | Travel and Lodging | Cash or cash equivalent | $410.95 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/20/2024 | SOBI, INC | VONJO (Drug) | Travel and Lodging | Cash or cash equivalent | $366.20 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/11/2024 | Geron Corporation | RYTELO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/10/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Consulting Fee | Cash or cash equivalent | $1,012.50 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $105.07 | General |
| Category: Hematology | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $83.99 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $29.41 | General |
| Category: Hematology | ||||||
| 12/08/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Consulting Fee | Cash or cash equivalent | $1,012.50 | General |
| Category: Immunology | ||||||
| 12/08/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $94.55 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $582.12 | General |
| 12/03/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $388.10 | General |
| Category: Hematology/Oncology | ||||||
| 11/12/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | Cash or cash equivalent | $57.26 | General |
| Category: Rare Disease | ||||||
| 11/12/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Rare Disease | ||||||
| 11/12/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | Cash or cash equivalent | $39.14 | General |
| Category: Rare Disease | ||||||
| 11/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,240.00 | General |
| Category: Rare Disease | ||||||
| 11/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | In-kind items and services | $236.73 | General |
| Category: Rare Disease | ||||||
| 11/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: Rare Disease | ||||||
| 11/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | Cash or cash equivalent | $92.06 | General |
| Category: Rare Disease | ||||||
| 11/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | Cash or cash equivalent | $82.97 | General |
| Category: Rare Disease | ||||||
| 11/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | In-kind items and services | $69.99 | General |
| Category: Rare Disease | ||||||
| 11/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | Cash or cash equivalent | $66.95 | General |
| Category: Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-486-AML-002 - A Phase 1/2 Dose and Schedule Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Azacitidine (CC-486) in Subjects with Acute Myelogenous Leukemia and | Celgene Corporation | $9,176 | 1 |
| Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (AZA-MDS-006) | Celgene Corporation | $4,962 | 1 |
| AZA-MDS-004 - A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS AND EFFECT OF FOOD OF A NEW TABLET FORMULATION OF ORAL AZACITIDINE, AND TO EVALUATE THE SAFETY AND EFFICACY OF ORAL AZACITIDIN | Celgene Corporation | $4,022 | 1 |
| AZA-MDS-004 | Celgene Corporation | $3,111 | 1 |
| MDS Patients selected from Jan 2006 and Feb 2014 GE Centricity EMR database to study of the use of disease-modifying therapy | Celgene Corporation | $3,111 | 1 |
| A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA | Takeda Pharmaceuticals U.S.A., Inc. | $2,100 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,736 | 2 |
| AZA-MDS-006 - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry | Celgene Corporation | $1,524 | 1 |
| CC-486-AML-002 | Celgene Corporation | $1,488 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 123 | 242 | $80,156 | $23,159 |
| 2022 | 4 | 88 | 177 | $47,515 | $15,162 |
| 2021 | 3 | 99 | 145 | $49,633 | $15,548 |
| 2020 | 7 | 141 | 296 | $81,244 | $23,176 |
Total Patients
451
Total Services
860
Medicare Billing
$77,045
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 34 | 55 | $23,984 | $6,545 | 27.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 50 | 84 | $23,201 | $6,424 | 27.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 61 | $19,631 | $6,212 | 31.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $7,137 | $2,016 | 28.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 29 | $6,203 | $1,964 | 31.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 71 | $20,178 | $6,283 | 31.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 50 | 80 | $17,555 | $5,931 | 33.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $8,222 | $2,362 | 28.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 11 | $1,560 | $586.95 | 37.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 39 | 66 | $27,619 | $8,018 | 29.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 44 | 63 | $14,059 | $4,966 | 35.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $7,954 | $2,564 | 32.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 17 | 106 | $27,027 | $9,614 | 35.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 31 | 55 | $21,709 | $4,965 | 22.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 32 | 47 | $13,430 | $3,109 | 23.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 27 | $5,173 | $1,712 | 33.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 20 | 30 | $5,429 | $1,346 | 24.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 13 | 13 | $5,190 | $1,275 | 24.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 17 | 18 | $3,286 | $1,155 | 35.2% |
About Bart Scott
Bart Scott is a Medical Oncology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285724138.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Bart Scott has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $273,956 received in 2024. These payments were reported across 1,368 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($878,231).
As a Medicare-enrolled provider, Scott has provided services to 451 Medicare beneficiaries, totaling 860 services with total Medicare billing of $77,045. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Seattle, WA
- Active Since 10/13/2006
- Last Updated 11/20/2012
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1285724138
Products in Payments
- JAKAFI (Drug) $251,264
- REBLOZYL (Biological) $133,965
- SOLIRIS (Drug) $90,297
- ULTOMIRIS (Biological) $86,122
- ONUREG (Drug) $80,864
- INQOVI (Drug) $70,771
- VYXEOS (Drug) $63,971
- VONJO (Drug) $52,555
- Revlimid (Drug) $51,198
- INREBIC (Drug) $47,930
- TIBSOVO (Drug) $36,007
- Empaveli (Drug) $33,600
- Vonjo (Drug) $28,678
- CC-486 (Drug) $24,431
- RYDAPT (Drug) $22,324
- AYVAKIT (Drug) $17,966
- Inrebic (Drug) $16,266
- Luspatercept (Drug) $10,937
- Ultomiris (Drug) $10,561
- JADENU (Drug) $9,384
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Seattle
Petros Grivas, M.d, M.D
Medical Oncology — Payments: $683,103
Medical Oncology $683,103
Evan Yu
Medical Oncology — Payments: $356,321
Medical Oncology $356,321
Gary Lyman, Md, MD
Medical Oncology — Payments: $176,021
Medical Oncology $176,021
Jerald Radich, Md, MD
Medical Oncology — Payments: $171,817
Medical Oncology $171,817
David Maloney
Medical Oncology — Payments: $167,323
Medical Oncology $167,323
Laura Chow, Md, MD
Medical Oncology — Payments: $156,359
Medical Oncology $156,359